Henlius Shares Surge in Early Trading Following NHS Inclusion Recommendation for Cancer Drug

Stock News07-02

HENLIUS (SEHK: 02696) shares experienced a significant rise of nearly 12% during the morning trading session.

At the time of reporting, the stock was up 7.07%, trading at HK$68.95 with a turnover of HK$52.73 million.

The upward movement follows a company announcement regarding its product, HANSIZHUANG® (serplulimab, European brand name: Hetronifly®).

According to the announcement from Henlius, its partner Accord Healthcare UK has confirmed that the drug has received a recommendation from the UK's National Institute for Health and Care Excellence (NICE).

This recommendation formally includes the medication within the routine clinical use scope of England and Wales' National Health Service (NHS) reimbursement system.

With the finalization of the NICE recommendation and completion of the NHS listing process, HANSIZHUANG® has become the first anti-PD-1 monoclonal antibody approved by NICE for the treatment of extensive-stage small cell lung cancer (ES-SCLC) in England and Wales.

Serplulimab is an immunotherapy drug that functions by aiding the body's own immune system to recognize and attack cancer cells.

The drug had previously received approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA), marking it as the first anti-PD-1 monoclonal antibody approved in the UK for ES-SCLC treatment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1119969085?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-02 11:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119969085","market":"other","top_or_hot":-1,"title":"Henlius Shares Surge in Early Trading Following NHS Inclusion Recommendation for Cancer Drug","media":"Stock News","content":"<p><b>HENLIUS</b> (<b>SEHK: 02696</b>) shares experienced a significant rise of nearly 12% during the morning trading session.<br><br>At the time of reporting, the stock was up 7.07%, trading at HK$68.95 with a turnover of HK$52.73 million.<br><br>The upward movement follows a company announcement regarding its product, HANSIZHUANG® (serplulimab, European brand name: Hetronifly®).<br><br>According to the announcement from Henlius, its partner Accord Healthcare UK has confirmed that the drug has received a recommendation from the UK's National Institute for Health and Care Excellence (NICE).<br><br>This recommendation formally includes the medication within the routine clinical use scope of England and Wales' National Health Service (NHS) reimbursement system.<br><br>With the finalization of the NICE recommendation and completion of the NHS listing process, HANSIZHUANG® has become the first anti-PD-1 monoclonal antibody approved by NICE for the treatment of extensive-stage small cell lung cancer (ES-SCLC) in England and Wales.<br><br>Serplulimab is an immunotherapy drug that functions by aiding the body's own immune system to recognize and attack cancer cells.<br><br>The drug had previously received approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA), marking it as the first anti-PD-1 monoclonal antibody approved in the UK for ES-SCLC treatment.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Henlius Shares Surge in Early Trading Following NHS Inclusion Recommendation for Cancer Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHenlius Shares Surge in Early Trading Following NHS Inclusion Recommendation for Cancer Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-02 11:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>HENLIUS</b> (<b>SEHK: 02696</b>) shares experienced a significant rise of nearly 12% during the morning trading session.<br><br>At the time of reporting, the stock was up 7.07%, trading at HK$68.95 with a turnover of HK$52.73 million.<br><br>The upward movement follows a company announcement regarding its product, HANSIZHUANG® (serplulimab, European brand name: Hetronifly®).<br><br>According to the announcement from Henlius, its partner Accord Healthcare UK has confirmed that the drug has received a recommendation from the UK's National Institute for Health and Care Excellence (NICE).<br><br>This recommendation formally includes the medication within the routine clinical use scope of England and Wales' National Health Service (NHS) reimbursement system.<br><br>With the finalization of the NICE recommendation and completion of the NHS listing process, HANSIZHUANG® has become the first anti-PD-1 monoclonal antibody approved by NICE for the treatment of extensive-stage small cell lung cancer (ES-SCLC) in England and Wales.<br><br>Serplulimab is an immunotherapy drug that functions by aiding the body's own immune system to recognize and attack cancer cells.<br><br>The drug had previously received approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA), marking it as the first anti-PD-1 monoclonal antibody approved in the UK for ES-SCLC treatment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"","article_id":"1119969085","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119969085","pubTimestamp":1782962305,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HENLIUS (SEHK: 02696) shares experienced a significant rise of nearly 12% during the morning trading session.At the time of reporting, the stock was up 7.07%, trading at HK$68.95 with a turnover of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","NICE":"NICE系统","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","BK4023":"应用软件","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","IE00BFMHRM44.USD":"NEUBERGER BERMAN GLOBAL EQUITY MEGATRENDS \"A\" (USD) ACC","BK1161":"生物科技","VXUS":"国际股票ETF-Vanguard","02696":"复宏汉霖","BK4543":"AI","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","BK4566":"资本集团"},"translate_title":"NHS建议纳入抗癌药物后，复宏汉霖股价早盘飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NICE":1,"VXUS":1,"02696":1},"content_text":"HENLIUS (SEHK: 02696) shares experienced a significant rise of nearly 12% during the morning trading session.At the time of reporting, the stock was up 7.07%, trading at HK$68.95 with a turnover of HK$52.73 million.The upward movement follows a company announcement regarding its product, HANSIZHUANG® (serplulimab, European brand name: Hetronifly®).According to the announcement from Henlius, its partner Accord Healthcare UK has confirmed that the drug has received a recommendation from the UK's National Institute for Health and Care Excellence (NICE).This recommendation formally includes the medication within the routine clinical use scope of England and Wales' National Health Service (NHS) reimbursement system.With the finalization of the NICE recommendation and completion of the NHS listing process, HANSIZHUANG® has become the first anti-PD-1 monoclonal antibody approved by NICE for the treatment of extensive-stage small cell lung cancer (ES-SCLC) in England and Wales.Serplulimab is an immunotherapy drug that functions by aiding the body's own immune system to recognize and attack cancer cells.The drug had previously received approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA), marking it as the first anti-PD-1 monoclonal antibody approved in the UK for ES-SCLC treatment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.0","shortVersion":"4.45.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1119969085","isCrawlerRequest":true}